tbuckley/cabot-search huggingface dataset:
Heat shock response inhibits cytokine-inducible nitric oxide synthase expression in rat hepatocytes
Authors: M DEVERA, Y KIM, H WONG, Q WANG, T BILLIAR, D GELLER
Journal: Hepatology (1996)

During sepsis or inflammation, the liver expresses various protective phenotypes such as the acute phase response or the heat shock response (HSR). Inducible nitric oxide synthase (NOS2) is also expressed in the liver in these conditions and may protect the liver under some circumstances and promote injury in others. We have previously reported that the acute phase response and NOS2 expression are differentially regulated, though both can be expressed simultaneously. The HSR is known to prevent expression of other genes, but its effects on NOS2 expression in the liver is unknown. Therefore, we examined how the HSR influences NOS2 expression in primary rat hepatocytes. Sodium arsenite (Ars) or hyperthermia (43 degrees C) induced the synthesis of hsp72 messenger RNA (mRNA) and protein in hepatocytes, indicating activation of the HSR. In the absence of the HSR, combinations of interleukin- 1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), and interferon gamma (IFN-gamma) stimulated high levels of NOS2 mRNA and nitric oxide (NO) synthesis. However, treatment with Ars or heat shock significantly attenuated cytokine-induced NOS2 mRNA and NO production. The addition of the nuclear factor kappaB (NF-kappaB) inhibitor pyrrolidine dithiocarbamate also inhibited NOS2 expression, suggesting a role for NF-kappaB in the cytokine induction of NOS2 in hepatocytes. Cytokines induced the appearance of an NF-kappaB complex as shown in gel retardation assays; however, induction of the HSR by Ars partially prevented cytokine-induced formation of this band while hyperthermia had a more complete inhibition. Furthermore, preinduction of the HSR prevented the activation of the NOS2 promoter construct in hepatocytes transfected with a 1.6 kilobase NOS2 promoter linked to luciferase. These findings show that NO production in stressed cells can be modulated by the HSR, possibly through repression of NOS2 gene transcription via the inhibition of NF-kappaB. (Hepatology 1996 Nov;24(5):1238-45)
Pediatrics
Authors: James Marvin Baty, Marshall B. Kreidberg, Orvar Swenson
Journal: New England Journal of Medicine (1952)

Congenital Malformation of the HeartThe pioneer advances in cardiac surgery of Gross75 and Blalock76 have greatly stimulated interest in the problems of congenital malformations of the heart. Surgical procedures that have been devised include treatment of patent ductus arteriosus, congenital vascular ring, coarctation of the aorta, tetralogy of Fallot, pulmonary stenosis, mitral stenosis and other anomalies of blood vessels.Cardiac catheterization is a safe and useful procedure in the study of cardiopulmonary physiology as well as in the diagnosis of congenital malformations of the heart. The work of Cournand,77 , 78 Bing,79 80 81 82 Dexter,83 McMichael84 and others on catheterization of the chambers . . .
Tangled bill.
Journal: BMJ (1967)

EDRInJU 519 symptomatically cured by posterior excisional ano-rectal myotomyl -a much less hazardous procedure than a definitive procedure.Paediatric surgeons will agree with Shim and Swenson on the advantages of these patients going to a large children's hospital with specialized departments of radiology, patho- logy, and biochemistry.In the field of neonatal emergency surgery it is essential that a team of highly skilled surgeons and pathologists must be available round the clock, as new- born victims of conditions such as Hirschsprung's disease usually present as an emergency.
Free thyroxine levels in critically ill patients. A comparison of currently available assays
Authors: M. F. Slag
Journal: JAMA (1981)

Two indices of free thyroxine (T<sub>4</sub>) and four methods of free T<sub>4</sub>measurement were compared in 85 patients with acute illness, hospitalized in intensive care units. All of the methods of free T<sub>4</sub>measurement in critical illness were nonspecific, and two of the methods failed to suggest hypothyroidism in two patients with primary hypothyroidism and another associated critical illness. Since the ideal screening test should be both sensitive and specific, all tests for free T4 used in this study should be interpreted with caution in severely ill patients. (<i>JAMA</i>1981;246:2702-2706)
Risk factors for persistent middle-ear effusions
Authors: K. D. Rogers
Journal: JAMA (1984)

<h3>In Reply.—</h3> The letter by Rogers et al details their objections to our analysis of the risk factors for persistent middle ear effusions. They claim that because household cigarette smoke exposure and an atopic history seem to be strongly related to nasal congestion, which in turn is strongly related to PMEE, the apparent associations of PMEE with cigarette smoke exposures and atopy are only artifactual. They support their assertion by noting that, when the data from Table 2 are adjusted for the presence of nasal congestion, there is then no difference in the proportion of cases and controls who were atopic or exposed to cigarette smoke. However, we believe that it is<i>inappropriate</i>to control for nasal congestion when assessing the risk for PMEE associated with exposures to household cigarette smoke and with atopy. This is because of our feeling that nasal congestion should not be considered as a confounder
Die Praxis der physikalischen Therapie. Ein Lehrbuch für Ärzte und Studierende.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABC of major trauma. Paediatric trauma: primary survey and resuscitation--I.
Authors: A R Lloyd-Thomas
Journal: BMJ (1990)

Trauma is the most common cause of death in childhood, with the aetiology of the injury varying with age.Road traffic accidents and falls account for childhood trauma 80% of injuriesEffective management in the first 20 minutes after an accident can do irs-Choking/suffocation, much to reduce morbidity and mortality in children with trauma.In those 'ni ng, fallIs who reach facilities alive the of preventable rs-Road traffic accidents death are errors in the management ofventilation and circulation and failure it of vehicle), burns, to detect hidden injuries.Therefore early participation of senior staff who ails are familiar with the surgical, anaesthetic, and medical management of children is essential.,ars-Road traffic accidents Because children are small multisystem injury is common.Thoracic and It or pedestrian), bicycle abdominal injuries are most commonly due to major blunt trauma, and, *ns, drowning unlike in adults, it is unusual to see penetrating injuries.Furthermore, appreciable damage to internal organs can occur without overlying bony fractures.Associated head trauma is more common. he paediatric trauma teamThe assessment of children with multiple r-Primary survey; secondary survey * Large head relative to body size * Small oral cavity with a relatively large tongue * 'Large angle of the jaw (infant 140°, adult 1200) * Epiglottis is more "U" shaped than in adults * Larynx is cephalad (glottis at C3 in infant, C5-6 in adults) with an anterior and inferior inclination * Cricoid ring is the narrowest part of the airway * Trachea is short (newborn 4-5 cm, at 18 months 7-8 cm) * Infants of 6 months or less are obligate nose breathers.Bilateral * Obstruction of upper respiratory tract * Oesophageal intubation Unilateral * Pneumothorax * Haemothorax * Lung contusion * Flail segment * Bronchial rupture *
Abstract P271: Association Between Nitric Oxide Synthase Gene Polymorphism ( <i>Glu298Asp</i> ) and Blood Pressure in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Jingkai Wei, Misa Graff, Lyn M Steffen, Kari E North, Yan Zheng, Gerardo Heiss
Journal: Circulation (2017)

Introduction: Endothelial NO synthase ( eNOS ) gene polymorphism at position 894 (G&gt;T, Glu298Asp ) resulting in a T allele is related to higher blood pressure (BP) levels, but the association of Glu298Asp and temporal increase in BP in adulthood has not been studied, nor is it known whether the association between Glu298Asp and BP is modified by habitual intake of fruits and vegetables, an abundant source of nitrate for conversion to NO. Hypothesis: We hypothesized that homozygous (TT) or heterozygous genotype (GT) status of Glu298Asp is associated with BP increase over a course of 9 years among black and white adults, compared to normal genotype (GG). Further, the association is amplified by higher habitual intake of fruits and vegetables. Methods: Among 9488 white (mean age: 54.3 years, 47.0% men) and 2861 black members of the ARIC cohort (mean age: 53.4 years, 37.2% men) at baseline (1987-1989), genotyping of the NOS3 Glu298Asp polymorphism (rs1799983) was conducted using the TaqMan assay (Applied Biosystems, Foster City, CA, USA). The rs1799983 levels 1.5-2, 0.5-1.49, &lt;0.5 were categorized as TT, GT, GG, respectively. We used the average of repeated sitting blood pressure at 4 cohort examinations through 1996-1998. Average intake of vegetables and fruit was calculated from food frequency questionnaires at exams 1 and 3, and analyzed as quartiles. A diet score without fruit and vegetables intake was created using principal component analysis. Mixed models were used to estimate the association between NOS3 G894T (TT or GT vs. GG) with level and change of SBP and DBP, adjusting for age, sex, genotypes, BMI, smoking status, diabetes, and physical activity. The analysis was also conducted within each quartile of vegetables and fruit intake, with further adjustment for the diet score without fruit and vegetables intake. Results: The genotypes of TT, GT and GG of Glu298Asp were present in 800 (8.4%), 4057 (42.8%), 4631 (48.8%) white participants, and 26 (0.9%), 510 (17.8%), 2335 (81.3%) black participants. Among whites with the genotype GT/TT, DBP increased 2.46 mmHg (95% CI: 0.02, 4.90) over 9 years compared to GG participants. The interaction between Glu298Asp and intake of fruit and vegetables was not statistically significant. There was no statistically significant association between GT/TT and SBP, nor with 9-year change of SBP or DBP among black participants. Conclusion: Carrier status of the GT/TT genotypes of Glu298Asp is associated with higher level of DBP among white adults, but not with SBP over a course of 9 years compared to the GG genotype of Glu298Asp . There is no interaction found between Glu298Asp and intake of fruit and vegetables in association with SBP or DBP.
Eighth Biannual Morris Hepatoma Symposium
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Eighth Biannual Morris Hepatoma Symposium Get access JNCI: Journal of the National Cancer Institute, Volume 68, Issue 4, April 1982, Page 695, https://doi.org/10.1093/jnci/68.4.695-d Published: 01 April 1982
Dental Treatment of Patients With Cerebral Palsy Made Easier
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Authors: P Portillo-Sanchez, T Schmidt, J Lakin
Journal: JAMA Internal Medicine (2016)

Caff eine Ingestion, Arrhythmias, and Heart Failure 1752In a double-blind randomized crossover clinical trial, Zuchinali and colleagues evaluated the acute eff ects of high-dose caff eine in 51 patients with heart failure with predominantly moderate-to-severe left ventricular systolic dysfunction, a population at increased risk for arrhythmic events.After 500 mg of caff eine administered over a 5-hour period, there was no statistically signifi cant eff ect of caff eine ingestion on the frequency of ventricular or supraventricular ectopies, bigeminal cycles and episodes of nonsustained tachycardia at rest and during a symptom-limited physical exercise.Kelly and Granger provide the Invited Commentary.
Venom Immunotherapy in Patients with Clonal Mast CELL Disorders: Efficacy, Safety and Practical Considerations
Authors: Patrizia Bonadonna, David Gonzalez-De-Olano, Roberta Zanotti, Annamaria Riccio, Laura De Ferrari, Carla Lombardo, Anthi Rogkakou, Luis Escribano, Ivan Alvarez-Twose, Almudena Matito, Arantza Vega, Giovanni Passalacqua
Journal: Journal of Allergy and Clinical Immunology (2013)
Combating a deadly combination: intravenous drug abuse, acquired immunodeficiency syndrome
Authors: C. A. Raymond
Journal: JAMA (1988)

1988 COULD be a year of particular focus on the intravenous drug abuser. A study released recently by Stephen C. Joseph, MD, health commissioner of New York City, and colleagues has renewed attention to the role of intravenous drug users in the epidemiology of acquired immunodeficiency syndrome (AIDS). Across the country, public health experts are devising new strategies to staunch the tide of human immunodeficiency virus (HIV) infections in this population. But these same experts say that characteristics of the illicit drug culture, as well as political constraints, may hinder their efforts. The New York study, reported at the annual meeting of the American Public Health Association, found that the number of AIDS-related deaths among intravenous drug abusers actually exceeded those occurring in homosexual men in New York. In a review of medical records of drug-related deaths, 2520 additional deaths attributed to AIDS were uncovered that were excluded in official
ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
Authors: J. Neoptolemos, M. Büchler, D. D. Stocken, P. Ghaneh, D. Smith, C. Bassi, M. Moore, D. Cunningham, C. Dervenis, D. Goldstein
Journal: Journal of Clinical Oncology (2009)

LBA4505 Background: Adjuvant 5-FU/FA (ESPAC-1 trial) and GEM (CONKO-001 trial) provide improved survival for patients with resected pancreatic cancer compared to no chemotherapy. The aim of the ESPAC-3 (v2) trial was to compare 5FU/FA vs GEM to identify if either adjuvant chemotherapy was associated with a significantly better survival. Methods: Patients with an R0/R1 resection for pancreatic ductal adenocarcinoma were randomized (stratified for resection margin status and country) &lt;8 weeks of surgery to receive either 5FU/FA (FA, 20 mg/m 2 , iv bolus injection followed by 5-FU, 425 mg/m 2 , iv bolus injection given 1–5d every 28 days) or GEM (1,000mg/m 2 iv infusion 1d, 8d and 15d every 4 weeks) for 6 months. The primary outcome measure was overall survival; the secondary measures were toxicity, progression free survival and quality of life. 1,030 patients were needed to detect a 10% difference in 2-year survival rates with 90% power. Results: 1,088 patients from 16 countries were randomized from July 2000 to Jan 2007 (5FU/FA = 551, GEM = 537). Median (range) age was 63 (31–85) years; 598 (55%) were men. Median tumor size was 30 (20–350) mm; 384 (35%) were R1 resections; 777 (72%) were node positive; and 263 (25%) were poorly differentiated tumors. Final analysis was carried out on an intention to treat basis with a minimum of 2 years follow-up after 753 (69%) patients had died. Median (IQR) follow-up of 335 alive patients was 34.2 (27.1–43.4) months, equal across treatment groups. Median survival from resection of patients treated with 5FU/FA was 23.0 (95% CI: 21.1, 25.0) months and for patients treated with GEM this was 23.6 (95%CI: 21.4, 26.4) months. Log-rank analysis revealed no statistically significant difference in survival estimates between the treatment groups (c 2 LR =0.7, p=0.39, HR GEM =0.94 (95%CI: 0.81, 1.08)). There was no significant difference in the effect of treatment across subgroups according to R status (test of heterogeneity c 2 1 =0.3, p=0.56). Conclusions: This is the largest adjuvant trial ever conducted for pancreatic ductal adenocarcinoma and showed no significant difference in survival between adjuvant 5FU/FA and adjuvant GEM. [Table: see text]
The journals of the AMA. From cooperation to consortium
Authors: G. Radulescu
Journal: JAMA (1986)

As of Sept 1, 1986,<i>JAMA</i>and the nine specialty journals<sup>*</sup>published by the American Medical Association (AMA) formally began to function as an editorial consortium. In succinct terms, this means that a manuscript rejected by one journal of the consortium for reasons of priority or unsuitability for that journal's readership may, with the author's agreement, be forwarded expeditiously for consideration by another AMA journal. The manuscript will be accompanied by the reviews obtained by the first editor, which should shorten the editorial review process appreciably the second time around. Several principles of functioning of the consortium are worth emphasizing to characterize its purpose: Because of the exigence of the review process, only a fraction of the manuscripts submitted to any AMA journal are accepted for publication. Some are rejected because of flaws in scientific quality. They are returned to the authors, accompanied by comments and recommendations, which may
Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
Authors: Philippe Rodon, Cyrille Hulin, Brigitte Pegourie, Mourad Tiab, Bruno Anglaret, Lotfi Benboubker, Henry Jardel, Olivier Decaux, Brigitte Kolb, Murielle Roussel, Laurent Garderet, Xavier Leleu, Olivier Fitoussi, Carine Chaleteix, Philippe Casassus, Pascal Lenain, Bruno Royer, Anne Banos, Riad Benramdane, Pascale Cony-Makhoul, Mamoun Dib, Jean Fontan, Anne-Marie Stoppa, Catherine Traulle, Jean-Pierre Vilque, Marie-Odile Petillon, Claire Mathiot, Hervé Avet-Loiseau, Philippe Moreau
Journal: Blood (2013)
Effects of Treatment on Morbidity in Hypertension
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum levels of transforming growth factor-α in patients after partial hepatectomy as determined with an enzyme-linked immunosorbent assay
Authors: T Tomiya
Journal: Hepatology (1993)

A sandwich enzyme-linked immunosorbent assay for measuring serum transforming growth factor-α levels was developed with monoclonal IgM and polyclonal IgG antihuman transforming growth factor-α antibodies and a system to amplify the activity of the conjugated enzyme. The assay detected serum transforming growth factor-α levels as low as 5 pg/ml. Serum transforming growth factor-α levels were below the detection limit of the assay in 19% of healthy adults, with a mean (± S.D.) detectable level of 22.0 ± 16.7 pg/ml. In 13 patients who underwent partial hepatectomy, serum transforming growth factor-α levels were determined serially after surgery. The levels were increased within 28 days of surgery in all the patients, with a mean maximal level of 118.2 ± 90.8 pg/ml. The maximal level achieved in each case correlated significantly with the resected volume of the liver and the increased volume of the remaining liver 28 days after hepatectomy (r = 0.59, p < 0.05, and r = 0.71, p < 0.005, respectively). In contrast, serum transforming growth factor-α levels showed no increase after laparotomy for nonhepatic surgery. Serum transforming growth factor-α levels may vary depending on the regenerative stimulus and reflect the degree to which liver regeneration will occur in patients after partial hepatectomy. (HEPATOLOGY 1993;18:304–308).
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer
Authors: W. M. Linehan
Journal: JAMA (1995)

RENAL carcinoma, the most common cancer of the kidney, occurs in over 27000 individuals in the United States each year and is responsible for over 11000 deaths annually.<sup>1</sup>The incidence of renal carcinoma worldwide has been increasing at an annual rate of approximately 2%.<sup>1</sup>Although renal carcinoma has been reported in children as young as 3 years, it most commonly occurs in adults between the ages of 50 and 70 years.<sup>2</sup>Renal carcinoma affects males twice as frequently as females and accounts for approximately 3% of adult cancers. Although a number of hormonal, environmental, cellular, and genetic factors have been evaluated, little is known about the etiology of renal cancer.<sup>3</sup>There is an increased incidence of renal cancer among workers exposed to asbestos and among leather workers,<sup>4,5</sup>and a strong correlation has been found with cigarette smoking.<sup>6,7</sup>In patients with end-stage renal disease, particularly